Loading
A study of 172 people, co-written by the test's inventor, reported that the Carcimun blood test separated people with cancer from healthy people and from people with inflammation.
Walter and colleagues evaluated the Carcimun test, which measures conformational changes in plasma proteins by optical extinction, in a prospective single-blinded study of 172 participants: 80 healthy volunteers, 64 people with cancers of various types and 28 with inflammatory conditions or benign tumours. Mean extinction values were higher in cancer (315.1) than in healthy people (23.9) or those with inflammation (62.7); the test distinguished the groups with accuracy 95.4%, sensitivity 90.6% and specificity 98.2%.
Small, with known cancers and no stage breakdown, and not independent of the inventor; it cannot say how the test would perform in people without symptoms.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/